The stock of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) is a huge mover today! The stock decreased 2.94% or $0.09 during the last trading session, hitting $2.97. About 994,318 shares traded hands or 42.73% up from the average. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) has declined 47.34% since February 29, 2016 and is downtrending. It has underperformed by 57.77% the S&P500.
The move comes after 7 months negative chart setup for the $107.72 million company. It was reported on Oct, 1 by Barchart.com. We have $2.58 PT which if reached, will make NASDAQ:AEGR worth $14.00 million less.
Analysts await Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) to report earnings on November, 14.
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Ratings Coverage
Out of 5 analysts covering Aegerion Pharmaceuticals (NASDAQ:AEGR), 3 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 60% are positive. Aegerion Pharmaceuticals has been the topic of 9 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating given on Wednesday, November 11 by Bank of America. Zacks upgraded the stock to “Hold” rating in Friday, August 7 report. The stock has “Buy” rating given by Guggenheim on Monday, December 21. The firm has “Underperform” rating given on Friday, February 12 by Bank of America. Jefferies upgraded the stock to “Buy” rating in Tuesday, July 28 report.
According to Zacks Investment Research, “Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutics to treat lipid disorders. Its products include Lomitapide and Implitapide. Lomitapide is a small molecule microsomal triglyceride transfer protein inhibitor, or MTP-I, that is used as an oral once-a-day treatment for patients with severe lipid disorders. Implitapide is used in the treatment of hypertriglyceridemia. Aegerion Pharmaceuticals, Inc. is headquartered in Bridgewater, New Jersey.”
More important recent Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) news were published by: Bostonglobe.com which released: “Aegerion Pharmaceuticals to merge with Canadian drug maker” on June 15, 2016, also Rttnews.com published article titled: “Aegerion Pharmaceuticals Inc. (AEGR) Is Up After Japanese Approval For JUXTAPID”, Bostonglobe.com published: “Aegerion to cut 13 percent of workforce” on July 20, 2016. More interesting news about Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) was released by: Prnewswire.com and their article: “Faruqi & Faruqi, LLP is Investigating Aegerion Pharmaceuticals, Inc. (AEGR) on …” with publication date: May 13, 2016.
AEGR Company Profile
Aegerion Pharmaceuticals, Inc., incorporated on February 4, 2005, is a biopharmaceutical company. The Firm is engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Firm operates through pharmaceuticals segment. The Company’s products include lomitapide and metreleptin.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.